m(6)A-related lncRNAs are potential biomarkers for predicting prognoses and immune responses in patients with LUAD.
m(6)A-related lncRNAs are potential biomarkers for predicting prognoses and immune responses in patients with LUAD.
复制标题
DOI：
10.1016/j.omtn.2021.04.003
复制
发表时间：
2021-06-04
期刊：
影响因子：
--
通讯作者：
Lin L
中科院分区：
文献类型：
--
作者：
Xu F;Huang X;Li Y;Chen Y;Lin L
肺腺癌（LUAD）是全世界最常见的肺癌亚型。然而，LUAD 患者的生存率仍然很低。 N6-甲基腺苷 (m6A) 和长链非编码 RNA (lncRNA) 在 LUAD 的预后价值和免疫治疗反应中发挥着至关重要的作用。因此，辨别 LUAD 患者中与 m6A 相关的 lncRNA 至关重要。本研究通过共表达的方式分析并获得了m6A相关的lncRNA。进行单变量、最小绝对收缩和选择算子（LASSO）和多变量Cox回归分析来构建m6A相关的lncRNA模型。使用Kaplan-Meier分析、主成分分析（PCA）、功能富集注释和列线图来分析风险模型。最后，还讨论了针对该模型的潜在免疫治疗特征和药物敏感性预测。包含 12 个 m6A 相关 lncRNA 的风险模型被确定为预后的独立预测因子。通过使用该模型对患者进行重新分组，我们可以在免疫治疗反应方面更有效地区分他们。最后，鉴定了针对 LUAD 亚型分化的候选化合物。这种基于 m6A 的 lncRNA 的风险模型可能有望用于 LUAD 患者预后和免疫治疗反应的临床预测。徐等人。构建并验证了基于 m6A 相关 lncRNA 的肺腺癌风险模型。这种风险模型可能有望用于肺腺癌患者预后和免疫治疗反应的临床预测。
Lung adenocarcinoma (LUAD) is the most frequent subtype of lung cancer worldwide. However, the survival rate of LUAD patients remains low. N6-methyladenosine (m6A) and long noncoding RNAs (lncRNAs) play vital roles in the prognostic value and the immunotherapeutic response of LUAD. Thus, discerning lncRNAs associated with m6A in LUAD patients is critical. In this study, m6A-related lncRNAs were analyzed and obtained by coexpression. Univariate, least absolute shrinkage and selection operator (LASSO), and multivariate Cox regression analyses were conducted to construct an m6A-related lncRNA model. Kaplan-Meier analysis, principal-component analysis (PCA), functional enrichment annotation, and nomogram were used to analyze the risk model. Finally, the potential immunotherapeutic signatures and drug sensitivity prediction targeting this model were also discussed. The risk model comprising 12 m6A-related lncRNAs was identified as an independent predictor of prognoses. By regrouping the patients with this model, we can distinguish between them more effectively in terms of the immunotherapeutic response. Finally, candidate compounds aimed at LUAD subtype differentiation were identified. This risk model based on the m6A-based lncRNAs may be promising for the clinical prediction of prognoses and immunotherapeutic responses in LUAD patients. Xu et al. constructed and validated a risk model based on m6A-related lncRNAs in lung adenocarcinoma. This risk model may be promising for the clinical prediction of prognoses and immunotherapeutic responses in lung adenocarcinoma patients.
登录
查看更多内容
乳腺癌干性相关 lncRNA 预后特征的鉴定和验证
影响因子：
7.4
作者：
Li, Xiaoying;Li, Yang;Jin, Feng
通讯作者：
Jin, Feng
N6-甲基腺苷相关 lncRNA 是预测低级别胶质瘤患者总体生存率的潜在生物标志物
影响因子：
5.5
作者：
Tu, Zewei;Wu, Lei;Zhu, Xingen
通讯作者：
Zhu, Xingen
影响因子：
5.7
作者：
Bade, Brett C.;Dela Cruz, Charles S.
通讯作者：
Dela Cruz, Charles S.
DOI：
10.1155/2018/6192187
发表时间：
2018
期刊：
Analytical cellular pathology (Amsterdam)
影响因子：
--
作者：
Jurišić V;Obradovic J;Pavlović S;Djordjevic N
通讯作者：
Djordjevic N
DOI：
10.1016/j.neo.2020.12.006
发表时间：
2021-03
期刊：
Neoplasia (New York, N.Y.)
影响因子：
--
作者：
Gong K;Guo G;Beckley N;Zhang Y;Yang X;Sharma M;Habib AA
通讯作者：
Habib AA